Advertisement
GLAS vs YCBD
Which Stock Would AI Choose? Glass House Brands (GLAS) vs. cbdMD (YCBD) Stock Comparison
Key Takeaways
- Both GLAS and YCBD operate in the cannabis and hemp-derived wellness space, but they differ sharply in scale, market positioning, and volatility.
- GLAS is a vertically integrated California cannabis producer with a larger revenue base and a "Strong Buy" analyst consensus, while YCBD is a micro-cap CBD and wellness brand builder pursuing acquisitions.
- Tickeron AI Verdict: Based on relative scale, lower volatility, and a clearer operational catalyst, the AI currently favors GLAS over YCBD.
- For more detail on these names, explore GLAS Major News and GLAS Today's Price Move, along with YCBD Major News and YCBD Today's Price Move.
- To see how automated strategies are navigating this market, visit the curated Trending AI Robots page.
Introduction
Investors comparing GLAS and YCBD are weighing two very different approaches to the evolving U.S. cannabis and CBD market. Glass House Brands is an established, vertically integrated cultivator and manufacturer focused on California, while cbdMD is a smaller consumer wellness company expanding through acquisitions into supplements and functional products. This stock comparison is relevant for traders tracking regulatory catalysts in cannabis, as well as for investors evaluating relative performance and market positioning between a larger, lower-beta operator and a high-volatility micro-cap. Both names carry meaningful risk, yet they offer contrasting exposure to the same broad industry theme.
GLAS Overview and Recent Performance
GLAS, or Glass House Brands Inc., is a vertically integrated cannabis company operating primarily in California, spanning cultivation, manufacturing, distribution, and retail under brands such as Glass House Farms, Plus, and Allswell. In recent months the company uplisted to the New York Stock Exchange (NYSE) and deconsolidated its retail operations while retaining a substantial economic interest, sharpening its focus on large-scale, low-cost biomass production. Recent market activity has been challenging: the stock has traded well below its 52-week high, with relative performance weakening amid mixed quarterly results, a wider net loss, and announced leadership transitions, including a planned CFO retirement. Analysts nonetheless retain a broadly constructive view, and the company has reported record production volumes alongside improving cost-per-pound economics, positioning it for potential interstate and export expansion as federal rescheduling progresses.
YCBD Overview and Recent Performance
YCBD, or cbdMD, Inc., develops and distributes hemp-derived CBD and wellness products under brands including cbdMD, Paw CBD, and ATRx. It recently completed the acquisition of Twinlab's operating assets, adding legacy supplement and sports-nutrition brands and broadening its portfolio beyond CBD. The company also integrated Bluebird Botanicals earlier in the year. Recent performance has been volatile: the stock trades near the lower end of its 52-week range, reflecting ongoing net losses, regulatory uncertainty, and a shareholder-authorized reverse stock split alongside potential dilution from convertible instruments. At the same time, revenue has grown on a trailing basis, and management points to the Centers for Medicare & Medicaid Services (CMS) Medicare pathway for hemp-derived CBD as a longer-term catalyst. The company's small market capitalization and elevated beta make its price behavior particularly sensitive to news flow.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a much larger catalog of hundreds of automated strategies that collectively trade thousands of different tickers. Because market conditions shift constantly, only the bots most suitable for the current environment earn a place in this featured section. These bots span diverse trading styles, strategies, timeframes, performance records, and statistical profiles, and each one focuses on its own set of tickers. This variety allows traders to review bots aligned with different risk tolerances and holding periods. For readers monitoring names like GLAS and YCBD, the page offers a practical way to observe how algorithmic systems approach volatile, catalyst-driven equities.
Head-to-Head Comparison
The two companies differ most clearly in scale and business model. GLAS generates substantially higher revenue through a vertically integrated, asset-heavy cultivation model concentrated in a single state, giving it cost advantages but also geographic and regulatory concentration risk. YCBD operates an asset-light, brand-driven model with a much smaller revenue base, pursuing growth through acquisitions that expand its product range but introduce integration and financing risks. On market sentiment, GLAS carries a "Strong Buy" consensus and lower beta, while YCBD trades with markedly higher volatility and faces dilution and reverse-split considerations. Growth drivers also diverge: GLAS is positioned around production scale and interstate or export opportunities, whereas YCBD leans on portfolio expansion and evolving federal reimbursement pathways. Both names are sensitive to shifting hemp and cannabis regulation.
Tickeron AI Verdict
Weighing observable factors such as relative scale, trend stability, volatility, and catalysts, Tickeron's AI would currently lean toward GLAS over YCBD. The preference reflects GLAS's larger revenue base, lower beta, and clearer operational levers tied to production efficiency and regulatory rescheduling, even as its recent downtrend warrants caution. YCBD's smaller capitalization, higher volatility, and financing-related overhang present a comparatively less stable risk profile, despite its growth catalysts. This assessment is probabilistic and based on current positioning rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLAS is a Hold and YCBD is a Hold.
GLAS's Stochastic Oscillator is remaining in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 27 of 36 cases over the following month. The odds of a continued upward trend are 75%.
GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for GLAS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
YCBD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for YCBD turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Oscillator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 85 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 148 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 33 cases where YCBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
YCBD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.568) is normal, around the industry mean (6.379). P/E Ratio (1.809) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
GLAS | YCBD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 40 Fair valued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 96 | 79 | |
P/E GROWTH RATING 1..100 | 6 | 27 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GLAS's Valuation (40) in the null industry is in the same range as YCBD (42) in the Other Consumer Services industry. This means that GLAS’s stock grew similarly to YCBD’s over the last 12 months.
GLAS's Profit vs Risk Rating (100) in the null industry is in the same range as YCBD (100) in the Other Consumer Services industry. This means that GLAS’s stock grew similarly to YCBD’s over the last 12 months.
GLAS's SMR Rating (98) in the null industry is in the same range as YCBD (98) in the Other Consumer Services industry. This means that GLAS’s stock grew similarly to YCBD’s over the last 12 months.
YCBD's Price Growth Rating (79) in the Other Consumer Services industry is in the same range as GLAS (96) in the null industry. This means that YCBD’s stock grew similarly to GLAS’s over the last 12 months.
GLAS's P/E Growth Rating (6) in the null industry is in the same range as YCBD (27) in the Other Consumer Services industry. This means that GLAS’s stock grew similarly to YCBD’s over the last 12 months.
| GLAS | YCBD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 66% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | N/A | 9 days ago 80% |
| Declines ODDS (%) | 3 days ago 88% | 7 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GLAS’s FA Score shows that 1 FA rating(s) are green while YCBD’s FA Score has 1 green FA rating(s).
- GLAS’s FA Score: 1 green, 4 red.
- YCBD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GLAS’s TA Score shows that 4 TA indicator(s) are bullish while YCBD’s TA Score has 4 bullish TA indicator(s).
- GLAS’s TA Score: 4 bullish, 3 bearish.
- YCBD’s TA Score: 4 bullish, 4 bearish.
Price Growth
GLAS (@Pharmaceuticals: Generic) experienced а -15.81% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was -8.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
GLAS is expected to report earnings on Nov 11, 2026.
YCBD is expected to report earnings on Dec 18, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
GLAS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GLAS has been loosely correlated with TRLV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GLAS jumps, then TRLV could also see price increases.
| Ticker / NAME | Correlation To GLAS | 1D Price Change % | ||
|---|---|---|---|---|
| GLAS | 100% | +2.60% | ||
| TRLV - GLAS | 64% Loosely correlated | +0.73% | ||
| CGC - GLAS | 63% Loosely correlated | -4.88% | ||
| TLRY - GLAS | 53% Loosely correlated | -7.02% | ||
| ACB - GLAS | 50% Loosely correlated | -0.97% | ||
| OGI - GLAS | 47% Loosely correlated | -2.69% | ||
More | ||||
YCBD and
Correlation & Price change
A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TRLV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TRLV could also see price increases.
| Ticker / NAME | Correlation To YCBD | 1D Price Change % | ||
|---|---|---|---|---|
| YCBD | 100% | +0.71% | ||
| TRLV - YCBD | 48% Loosely correlated | +0.73% | ||
| GLAS - YCBD | 43% Loosely correlated | +2.60% | ||
| TLRY - YCBD | 41% Loosely correlated | -7.02% | ||
| CRON - YCBD | 25% Poorly correlated | -3.67% | ||
| DERM - YCBD | 24% Poorly correlated | -2.21% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FHLC | 90.20 | 0.16 | +0.18% |
| Fidelity MSCI Health Care Index ETF (FHLC) | |||
| GLRY | 37.68 | 0.05 | +0.13% |
| Inspire Growth ETF (GLRY) | |||
| FRIZ | 27.79 | N/A | N/A |
| Franklin Dividend Growth ETF (FRIZ) | |||
| CPRJ | 27.50 | -0.03 | -0.11% |
| Calamos Russell 2000 Structured Alt Protection ETF July (CPRJ) | |||
| FNY | 98.31 | -0.45 | -0.46% |
| First Trust Mid Cap Growth AlphaDEX Fund (FNY) | |||